SLB (SLB): 2Q26 First Take: EBITDA Beat on Stronger Revenue and Margins vs GS; Focus on International Commentary on Call

Research evidence excerpt

SLB (SLB): 2Q26 First Take: EBITDA Beat on Stronger Revenue and Margins vs GS; Focus on International Commentary on Call

potential and/or the likelihood of the realization of the return across

their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or

other designated committee in each respective region and do not represent a change in the analysts’ investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or

anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total

return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at

https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when

Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or

policy constraints due to Goldman Sachs’ involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment

rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that

has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device.